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Abstract
The introduction of adjuvant systemic therapy led to a significant improvement in post-
surgical survival and a reduction in disease relapse. Approximately 75–80% of all breast
cancers are hormone-dependent based on the presence of ER and/or PR on tumor cells.
Patients with HR+ breast cancer less than 5 mm and treated with only endocrine therapy
have usually very good prognosis. They typically are not treated with adjuvant chemo-
therapy. The patients with stage III HR+ breast cancer still require adjuvant chemotherapy
since they carry high risk of recurrence without chemotherapy. Many patients with HR+
HER2 negative breast cancer fall in between these two categories, and they are called as
intermediate risk group based on clinicopathological variables, genomic tests or online
risk calculators. The minimum duration of adjuvant endocrine treatment is 5 years; how-
ever, patients with high risk factors including positive lymph node should be treated with
the endocrine therapy up to 10 years either with tamoxifen alone or sequentially with
aromatase inhibitors (AI) in postmenopausal women. Adjuvant bisphosphonates reduce
bone recurrence and improve survival in postmenopausal women with early stage breast
cancer.
Keywords: adjuvant chemotherapy, breast cancer, endocrine therapy, hormone receptor,
molecular assays
1. Introduction
Breast cancer is the most common cancer accounting for 25.1% of all cancers in women
according to GLOBOCAN and the second most common cancer overall worldwide [1]. Over
1.5 million women are diagnosed with breast cancer every year, and half million women die
due to breast cancer in the world each year. Although it is the fifth most common cause of
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death from cancer in women, during last 3 decades, deaths due to breast cancer have
decreased by one-third or more. It is due in part to increased screening, as well as more
effective loco-regional and systemic treatment options have been established over last decades.
The risk of relapse varies substantially on the basis of individual disease. Thus, accurate
estimates regarding recurrence and survival are critical for selecting patients with breast
cancer who will benefit from adjuvant therapy. Decisions about the type of treatment have
traditionally been based on the histopathologic parameters including lymph node status,
tumor size, histologic grade, histologic subtype, patient age, and estrogen receptor (ER)/pro-
gesterone receptor (PR) status. However, these characteristics fail to characterize the biologic
heterogeneity of tumors, which has important implications for treatment benefit. The advent of
microarray gene expression profiles as well as sequencing of the whole genome has brought
several multigene platforms into clinical use. Many of these platforms incorporate traditional
markers (e.g., ER, PR, and HER2) as well as additional cancer-associated genes. Approxi-
mately 75–80% of all breast cancers are luminal A or luminal B subtypes which are hormone-
dependent based on the presence of ER and/or PR on tumor cells [2].
Here, the genetic and online tools which guide the adjuvant systemic treatment, options of
endocrine therapy and systemic cytotoxic chemotherapy in patients with early stage HR+,
HER2 -negative breast cancer will be discussed.
2. Treatment decision tools
Adjuvant systemic treatments reduce the risk of breast cancer recurrence following the local
treatment of primary stage I–III breast cancers. International expert groups recommend deter-
mining the histologic grade and ER, PR, Ki-67 and HER2 status in all breast cancer patients, in
order to assist prognosis and determine therapeutic options, including hormone therapy,
chemotherapy and anti-HER2 therapy.
For patients with HR+ breast cancers receiving hormonal therapy, the risk of distant recurrence
is under 20% and therefore, many patients may potentially be spared of chemotherapy. The
web-based prognostification and treatment benefit tools and genomic assays have been incor-
porated into treatment planning for patients with early-stage HR+ breast cancer, which lead to
get more information about prognosis and prediction of treatment response. These assays
supplement the traditional histopathologic markers and help identify patients at high risk of
recurrence. They also provide a more quantitative approach to risk assessment and enable
individualization of treatment. This has both quality of life and health care cost implications
because patients who will not benefit from a certain treatment can be spared both the toxicity
and the expense [3].
One of the available genetic prognostic platforms (MammaPrint®, Oncotype DX®, Prosigna®
or EndoPredict®) may be used in node-negative ER+ patients to establish a prognostic
category and decide with the patient whether adjuvant treatment may be limited to hor-
monal therapy.
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2.1. Genomic tools: oncotype Dx
Oncotype DX contains five reference genes (ACTB, GAPDH, GUS, RPLPO and TFRC) and 16
cancer-related genes. RNA is extracted from formalin-fixed paraffin-embedded tumor tissue,
using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). The
recurrence score (RS) is the result of a mathematical formula of the weighted expression of each
gene, ranging from 0 to 100. The cutoff points are divided into three categories: low risk (RS < 18),
intermediate risk (RS 18–30), and high risk (RS > 31). The RS has been proved to be a predictor of
10-year distant recurrence for early breast cancer through NSABP B-14 in multivariate analyses
including age, tumor size, tumor grade, ER status and HER2 status [4]. Furthermore, patients
with low or intermediate RS had large improvements in disease-free survival (DFS) if treated
with tamoxifen (TAM), which indicated that RS was helpful in evaluating treatment response to
endocrine therapy in early breast cancer. Habel et al. [5] conducted a case–control study among
women with ER+, node-negative breast cancer treated with TAM and compared these with
untreated patients. The RS was associated with the risk of breast cancer death in both groups
(P = 0.003 and P = 0.03). Thus, the RS was strongly related to long-termmortality of breast cancer
among ER+ breast cancer patients treated with endocrine therapy.
Paik et al. not only evaluated the relationship between the RS and clinical result of ER+, node-
negative early breast cancer but also explored the prognostic ability in late recurrence of breast
cancer [4]. The 10-year distant recurrence rate was 6.8% in low-risk group, 14.3% in
intermediate-risk group and 30.5% in high-risk group. The RS was shown to be related to
distant relapse in patients who did not receive adjuvant chemotherapy, regardless of age and
tumor size and performed better than both of them (P < 0.001).
RS can predict chemotherapy sensitivity in patients with ER+, node-negative breast cancer [6].
Paik et al. studied 651 cases of breast cancer who were enrolled in NSABP B-20 and randomly
assigned them into a TAM group and a TAM combined with the chemotherapy group [che-
motherapy regimen for cyclophosphamide & methotrexate & fluorouracil (CMF) or MF regi-
men, TAM + CMF/MF group] [4]. The 10-year follow-up results showed that patients with high
RS had benefited from cytotoxic chemotherapy, with the 10-year metastasis rate being
decreased by 27.6%. In contrast, the 10-year distant metastasis rate was decreased by an
average of 1.1% in patients with low RS who received adjuvant chemotherapy. Therefore,
patients with ER+ early breast cancer and high RS should benefit from chemotherapy, while
patients with low RS cannot. RS can help select patients who experience little benefit of
chemotherapy and can avoid the toxic effects of chemotherapy.
In a phase III trial, the Trial Assigning Individualized Options for Treatment (TAILORx), there
was a prospective phase to further validate the function of RS in patients with HR+, HER2-
negative, node-negative breast cancer. The results from TAILORx indicated that patients with
very low RS results (<11) had excellent clinical outcome with a rate of 5-year freedom from
distant recurrence with endocrine therapy at 99.3% and a rate of overall survival (OS) of 98.0%,
even without chemotherapy [7]. As for its excellent utility in identifying patients with good
outcome, Oncotype DX RS became the only gene-expression assay that was recommended at
level I evidence in the AJCC Prognostic Stage Group. In patients with HR+, node-negative
breast cancer, the RS showed excellent clinical utility to predict clinical outcomes.
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In ECOG E2197, the predictive utility of RS on loco-regional recurrence (LRR) was evaluated in
388 patients with N0-N1 involvement and treated with breast conserving surgery, chemo-
endocrine therapy and breast irradiation. The 10-year rates of LRR for HR+ tumors were
shown to be 3.8, 5.1 and 12.0% for low, intermediate and high risk of RS (P = 0.12) [8].
In NSABP B-28 trial, RS was shown to be a statistically predictor of LRR, with 10-year
cumulative incidence of LRR of 3.3, 7.2 and 12.2% in low, intermediate and high RS
(P < 0.001) [9]. RS is a strongly predictive factor of LRR for HR+ breast cancer regardless of
node status. Another study, PACS 01 trial, with a median of 7.7 years follow-up, showed that
RS was a significant predictor of distant recurrence free interval survival, disease-free survival
(DFS) and OS (P < 0.001) in HR+, node-positive patients treated with chemotherapy plus
endocrine therapy [10].
The Southwest Oncology Group (SWOG)-8814 focused on exploring the benefit of therapy in
patients with HR+, node-positive breast cancer. It enrolled postmenopausal women treated
with chemotherapy or simple endocrine adjuvant therapy, of which 367 cases (40%) received
an RS detection. RS had a definite predictive value (P = 0.016) for adjuvant treatment benefit
over 5 years and was poorly predicted for treatment beyond 5 years (P = 0.87). High-risk
patients receiving chemotherapy combined with endocrine therapy compared with simple
endocrine therapy benefit significantly (P = 0.033). SWOG-8814 trial showed that the RS was
also prognostic for TAM-treated patients with positive nodes and predicts significant benefit
of chemotherapy [cyclophosphamide & adriamycin & fluorouracil (CAF)] in tumors with a
high RS [11].
In a recent prospective phase III trial, West German Study Group Plan B, 348 patients (15.8%)
with RS ≤ 11 had excellent 3-year survival even if they omitted chemotherapy. The 3-year
DFS in patients with RS ≤ 11 was 98%, in which 41.1% had node-positive and 32.5% were
grade 3 disease. These were the first prospective data to report clinical outcome when RS was
used to make physical decision in patients with HR+ breast cancer regardless of lymph node
invasion [12].
Rx for Positive Node, Endocrine Responsive Breast Cancer (RxPONDER) trial is an ongoing
multicenter phase III trial revealed that patients with node positive breast cancer who had low
to intermediate RS results could benefit from chemotherapy [13]. The trial also determined
whether there is an optimal RS cutoff for these patients above which chemotherapy should be
recommended in clinical practice. RxPONDER trial randomized patients with HR+, HER2-
negative and 1–3 lymph nodes breast cancer with RS ≤ 25, to improve the risk of stratification
in patients with low or intermediate RS.
2.2. MammaPrint
MammaPrint was first developed by the Netherlands Cancer Institute group. van’t Veer et al.
[14] used a gene-expression panel to detect 78 frozen tumor tissues from patients with pT1-2cN0
invasive breast carcinoma who had received standard treatment. Ribonucleic acid was isolated
from fresh frozen tumor tissue to obtain complementary DNA. The gene-expression panel
contains 70 genes related to early risk of metastasis, including tumor invasion, metastasis,
interstitial invasion, and angiogenesis-related genes.
Breast Cancer and Surgery126
The MINDACT study was a randomized trial that included 6693 women with histologically
proven operable N0/N1 invasive breast cancer without distant metastases [15]. Patients were
recruited from 2007 to 2011. Initially, only patients without regional lymph node metastasis
were enrolled. The study was amended to include patients with 1–3+ nodes in 2009.
MammaPrint assay was used to determine participant’s genomic risk and a modified version
of Adjuvant! Online (version 8.0 with HER2 status) was used to determine clinical risk [16, 17].
Patients with both low clinical and low genomic risk were not treated with adjuvant chemo-
therapy; on the other hand, patients with high clinical and high genomic risk received adjuvant
chemotherapy. The patients with discordant clinical and genomic risk results (high/low or low/
high) were randomized to receive chemotherapy or not to receive chemotherapy. All patients
were recommended to receive 7 years of hormonal therapy.
Patients at low clinical risk but high genomic risk who received chemotherapy had a 5-year
distant metastasis free survival of 95.8% compared with 95.0% among those who did not
receive chemotherapy. The adjusted hazard ratio for distant metastasis or death with chemo-
therapy versus no chemotherapy in this group was 1.17 (P = 0.66). Thus, a chemotherapy
benefit is unlikely in women with tumors at low clinical risk regardless of genomic subtype.
If a patient has ER/PgR-positive, HER2-negative, node negative, breast cancer, the
MammaPrint (Agendia) assay should not be used in those with low clinical risk per
MINDACT categorization to inform decisions on withholding adjuvant systemic chemother-
apy because women in the low clinical risk category had excellent outcomes and did not
appear to benefit from chemotherapy even with a genomic high-risk cancer.
If a patient has HR+, HER2-negative, node-negative breast cancer, the MammaPrint assay may
be used in those with high clinical risk to inform decisions on withholding adjuvant systemic
chemotherapy due to its ability to identify a good-prognosis population with potentially
limited chemotherapy benefit. Women in the low clinical risk category did not benefit from
chemotherapy regardless of genomic MammaPrint risk group. Therefore, the MammaPrint
assay does not have clinical utility in such patients.
If a patient has HR+, HER2-negative, node-positive breast cancer, the MammaPrint assay may
be used in patients with 1–3 positive nodes and a high clinical risk to inform decisions on
withholding adjuvant systemic chemotherapy. However, such patients should be informed
that a benefit from chemotherapy cannot be excluded, particularly in patients with greater
than one involved lymph node.
The clinician should not use the MammaPrint assay to guide decisions on adjuvant systemic
therapy in patients with HR+, HER2-negative, node-positive breast cancer at low clinical risk,
nor any patient with HER2-positive or triple-negative breast cancer, because of the lack of
definitive data in these populations [18].
2.3. PAM-50: PROSIGNA
The PAM50 Breast Cancer Intrinsic Classifier™ assay (ARUP Laboratories, Salt Lake City, UT)
is a standardized test measuring 50 classifier genes and five control genes, amenable to assay
by techniques such as quantitative real-time reverse transcriptase PCR [19]. It was originally
developed in a microarray-based cohort of node-negative, untreated breast cancer patients. It
Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast Cancer
http://dx.doi.org/10.5772/intechopen.76578
127
accurately identifies the major intrinsic biological subtypes of breast cancer commonly known
as luminal A, luminal B, HER2 enriched, and basal-like [20] and predicts the risk of recurrence
(ROR) at 10 years. Tumors that are named as luminal A in PAM50 intrinsic subtype indicate
usually very good prognosis with only adjuvant endocrine therapy, whereas luminal B sub-
types have increased risk of recurrence without adjuvant chemotherapy.
Four versions of ROR exist in the research setting: ROR based on subtype information (ROR-S),
ROR-S with proliferation (ROR-P), ROR-S with tumor size (ROR-T), and ROR-P with tumor
size (ROR-PT) [20]. The minimum ROR score of all Luminal B scores was assigned as the low-
risk threshold for each model and the maximum ROR score of all Luminal A scores as the
high-risk threshold [20]. Large validation studies (ATAC and ABCSG8) for the PAM50 assay
were performed using the standardized version with pre-specified cutoffs based on actual
survival outcomes (<10, 10–20, and > 20% risk of distant relapse at 10 years) and not subtype
distribution [21].
The Prosigna Breast Cancer Prognostic Gene Signature Assay is an in vitro diagnostic assay,
which is performed on the NanoString nCounter® Dx Analysis System using FFPE breast
tumor tissue previously diagnosed as invasive breast carcinoma. The Prosigna Score is a
numerical value on a 0–100 scale that correlates with the probability of distant recurrence
within 10 years. The gene expression profile of a patient’s tumor is compared with each of the
four PAM50 prototypical molecular profiles to determine the degree of similarity. The results
in combination with a proliferation score and tumor size produce an individualized Prosigna
Score. This qualitative assay utilizes gene expression data, weighted together with clinical
variables to generate a risk category and numerical score, to assess a patient’s risk of distant
recurrence of disease.
In node-negative patients, the 10-year distant recurrence-free survival (DRFS) rates were > 95%
for the low-risk group, 90.4% for the intermediate-risk group, and < 85% for the high-risk
group [22, 23]. In node-positive patients, the 10-year DRFS rates were 94.2% for the low-risk
group and 75.8% for the high-risk group [22].
The Prosigna Breast Cancer Prognostic Gene Signature Assay is indicated in female breast
cancer patients who have undergone surgery in conjunction with locoregional treatment
consistent with standard of care, either as:
i. A prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal
women with HR+, lymph node-negative, stage I or II breast cancer to be treated with
adjuvant endocrine therapy alone, when used in conjunction with other clinicopatholog-
ical factors.
ii. A prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal
women with HR+, lymph node-positive (1–3 positive nodes), stage II breast cancer to be
treated with adjuvant endocrine therapy alone, when used in conjunction with other
clinicopathological factors.
The assay should not be used for patients with four or more positive nodes.
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2.4. EndoPredict
The EndoPredict (EP) assay combines the expression of three proliferative and five ER-
signaling/differentiation-associated genes and is normalized by three housekeeping genes
[24]. EP may be measured in formalin-fixed, paraffin-embedded tissue sections by quantitative
real-time polymerase chain reaction in decentralized laboratories and provides a score that
ranges between 0 and 15 after scaling [25].
EPclin was derived from EP by incorporating nodal status and tumor size to create an inte-
grated diagnostic algorithm for clinical decisions [24]. Both EP and EPclin were trained on a
cohort of 964 patients with ER+, HER2-negative carcinomas treated with adjuvant endocrine
therapy only. Thresholds for EP and EPclin to differentiate between patients at low or high risk
corresponding to a 10% probability of distant recurrence at 10 years were set at 5 and 3.3,
respectively. Patients with an EP score < 5 (EPclin score < 3.3) were classified as low risk for
distance recurrence, whereas patients with an EP score ≥5 (EPclin score ≥3.3) were stratified as
high risk. Both EP and EPclin were shown to be prognostic for early and late distant recurrence
in the ABCSG-6 and ABCSG-8 trials involving patients with ER+/HER2-negative breast cancer
treated with adjuvant endocrine therapy only [26]. EndoPredict provides prognostic informa-
tion beyond all common clinicopathological parameters and clinical guidelines.
There are several prognostic multigene-based tests for managing breast cancer, but limited
data comparing them in the same cohort. The prognostic performance of the EP test was
compared with the research-based PAM50 non-standardized qRT-PCR assay in node-positive
ER+ and HER2-negative breast cancer patients receiving adjuvant chemotherapy followed by
endocrine therapy (ET) in the GEICAM/9906 trial [27]. EP and PAM50 ROR scores [based on
subtype (ROR-S) and on subtype and proliferation (ROR-P)] were compared in 536 ER+/
HER2patients. Scores combined with clinical information were evaluated: ROR-T (ROR-S,
tumor size), ROR-PT (ROR-P, tumor size), and EPclin (EP, tumor size, nodal status). Patients
were assigned to risk categories according to prespecified cutoffs. ROR-S, ROR-P, and EP
scores identified a low-risk group with a relative better outcome (10-year distant metastasis-
free survival: ROR-S 87%; ROR-P 89%; EP 93%). No significant difference between tests was
found. Predictors including clinical information showed superior prognostic performance
compared to molecular scores alone (10-year MFS, low-risk group: ROR-T 88%; ROR-PT 92%;
EPclin 100%). The EPclin-based risk stratification achieved a significantly improved prediction
of MFS compared to ROR-T, but not ROR-PT. All signatures added prognostic information to
common clinical parameters.
EPclin provided independent prognostic information beyond ROR-T and ROR-PT. ROR and
EP can reliably predict risk of distant metastasis in node-positive ER+/HER2 negative breast
cancer patients treated with chemotherapy and ET. Addition of clinical parameters into risk
scores improves their prognostic ability.
Recently, in a secondary analysis of a randomized clinical trial, the prognostic value of six
multigene signatures was compared in women with early ER+ breast cancer [28]. In this study,
774 postmenopausal women with ER+, HER2-negative disease, 591 had node-negative disease
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and patients received endocrine therapy for 5 years (the Anastrozole or Tamoxifen Alone or
Combined randomized clinical trial comparing 5-year treatment with anastrozole vs. tamoxi-
fen) in addition to the Clinical Treatment Score (nodal status, tumor size, grade, age, and
endocrine treatment) for distant recurrence for 0–10 years and 5–10 years after diagnosis [28].
The signatures included the Oncotype Dx recurrence score, ROR, Breast Cancer Index (BCI),
EPclin, Clinical Treatment Score, and 4-marker immunohistochemical score. The ROR (HR,
2.56), followed by the BCI (HR, 2.46) and EPclin (HR, 2.14) were shown to be the signatures
which have the most prognostic information. Each provided significantly more information
than the Clinical Treatment Score (HR, 1.99), the recurrence score (HR, 1.69), and the 4-marker
immunohistochemical score (HR, 1.95). Substantially less information was provided by all six
molecular tests for the 183 patients with 1–3 positive nodes, but the BCI and EPclin provided
more additional prognostic information than the other signatures. For women with node-
negative disease, the ROR, BCI, and EPclin were shown to be significantly more prognostic
for overall and late distant recurrence. For women with 1–3 positive nodes, limited indepen-
dent information was available from any test.
2.5. Breast cancer index
The breast cancer index assay previously has been developed and validated. It consists of two
independently developed gene expression biomarkers: molecular grade index (MGI) and
HOXB13/IL17BR (H/I) [20, 26]. MGI, a 5-gene predictor that recapitulates tumor grade/prolif-
eration, is highly prognostic in ER+ breast cancer patients. H/I, which was developed indepen-
dent of tumor grade/proliferation, is prognostic for early and late distant recurrences and is
predictive of extended adjuvant AI benefit in early stage of ER+ breast cancer patients.
2.6. Online prognostification and prediction tools
The online tools referred to earlier primarily use clinicopathological variables and cancer
registry data as the basis of risk prediction. The clinical pathological variables used include
age, tumor size and grade, mode of detection, number of lymph nodes involved, ER status,
HER2 status, Ki67 status and type of chemotherapy [29].
2.6.1. Adjuvant online
Adjuvant!Online is a free online tool and probably the most widely used tool that estimate
risks and benefits of adjuvant endocrine therapy and chemotherapy after breast cancer surgery
based on factors, such as the patient’s stage, pathologic features, age and comorbidity level.
Entering information on age and selected tumor characteristics (tumor size and grade, number
of positive axillary nodes, and hormone receptors status) allows for prediction of the 10-year
risk of relapse-free and overall survival.
Despite these strengths, Adjuvant! has several limitations. The relapse estimates include local-
regional recurrence as well as distant metastases; this is important as the proportions of both
may vary greatly depending on stage and tumor phenotype. The baseline risk estimation for
Adjuvant! Online was derived from the SEER (surveillance, epidemiology and end results)
database [30]. The SEER database program is a collation of nine databases covering one-sixth
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of the US population. There have been concerns regarding the quality of the data about cause
of death [31]. Additionally, the SEER database specifically includes patients between 35 and
69 years and provides limited information on the socio-economic status of people.
Adjuvant! Online tends to overestimate the number of patients at high risk. Cardoso et al.
reported that Adjuvant! Online classified 23% of patients as high clinical risk when Oncotype
DX classified them as low genomic risk [15].
Olivotto et al. performed a population-based validation study and suggested that Adjuvant!
Online would overestimate survival in patients under 35 years of age with lymphovascular
invasion. It was also found that Adjuvant! Online tends to overestimate the survival rates of
younger women with ER+ breast cancer [16] and that it overestimated the added value of
chemotherapy for older patients [32].
The validity of the predictive score is calculated by Adjuvant! Online was deemed weak in the
clinician-based validation [33]. Predictions on loco-regional relapse and distant metastases
may vary greatly, making it difficult to make clear recommendations for adjuvant treatment
[34]. This is reflected in two studies that suggest that when patients are involved in a discus-
sion to decide on adjuvant chemotherapy, they are less likely to choose chemotherapy if using
Adjuvant! Online [35].
The database does not include information regarding the benefits of adjuvant trastuzumab,
thereby reducing the utility of Adjuvant! Online in clinical decisions about HER2-positive
disease treatment [31]. This deficiency of Adjuvant! Online with regard to HER2-positive
disease has significant implications for the prediction of metastatic spread. In a recent in vitro
study using murine models, the HER2 status of cells predicted the response to progesterone-
induced signaling, with HER2-deficient cells being more likely to migrate and HER2-enriched
cells tending toward increased proliferation [36]. This recent evidence underlines the impor-
tance of HER2 in predicting prognosis and highlights the significance of this inherent short-
coming in online cancer registry-based prognostic tools.
The ethnic variation in the data on which these online tools are based seriously affects the
generalizability of these online tools. The SEER database is representative of the usual US
population in terms of age, sex and ethnic distribution. However, the ethnic mix of the US
population is different from that of England and Wales [37].
2.6.2. Predict
Predict is an another online prognostication and treatment benefit tool based on UK cancer
registry data and included information on 5694 women treated in East Anglia from 1999 to
2003 [38]. It is designed to help clinicians and patients make informed decisions about treat-
ment following breast cancer surgery. The model was validated in a second UK cancer registry
dataset. It would able to provide not only the accurate prediction of survival but also subse-
quent calculation of treatment benefit.
Data of an individual patient including patient age, tumor size, tumor grade, number of
positive nodes, ER status, HER2 status, KI67 status and mode of detection are submitted to
online PREDICT tool. It originally did not include HER2 status and KI67 status, but in 2011,
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HER2 status was included (PREDICT version 1.1) and later KI67 was added to model (PRE-
DICT version 1.2) to improve the estimates of breast cancer-specific mortality, especially in
HER2-positive patients [29, 39].
While the overall fit of the model has been good in multiple independent case series, PREDICT
has been shown to underestimate breast cancer specific mortality in women diagnosed under
the age of 40, particularly those with ER+ disease. Another limitation of the model is the use of
discrete categories for tumor size and node status which result in “step” changes in risk
estimates on moving from one category to the next. For example, a woman with an 18 or
19 mm tumor will be predicted to have the same breast cancer specific mortality if all the other
prognostic factors are the same whereas breast cancer-specific morality of women with a 19 or
20 mm tumor will differ. The PREDICT prognostic model was refitted using the original cohort
of cases from East Anglia with updated survival time in order to take into account age at
diagnosis and to smooth out the survival function for tumor size and node status. The fit of the
model has been tested in three independent data sets that had also been used to validate the
original version of PREDICT [40].
KI67 positivity for the PREDICTmodel was defined as greater than 10% of tumor cells staining
positive. Survival estimates, with and without adjuvant therapy, are presented in visual and
text formats. Treatment benefits for hormone therapy and chemotherapy are calculated by
applying relative risk reductions from the Oxford overview to the breast cancer specific mortal-
ity. Predicted mortality reductions are available for both second-generation (anthracycline-
containing, >4 cycles or equivalent) and third-generation (taxane-containing) chemotherapy
regimens. The survival estimates, presented both with and without adjuvant hormone therapy,
chemotherapy and trastuzumab, are provided for 5 and 10 years.
The Cambridge Breast Unit uses the absolute 10-year survival benefit from chemotherapy to
guide decision-making for adjuvant chemotherapy as follows: <3% no chemotherapy; 3–5%
chemotherapy discussed as a possible option; >5% chemotherapy recommended.
Online tools are valuable in guiding adjuvant treatment, especially in resource-constrained
countries. However, in the era of personalized therapy, molecular profiling appears to be
superior in predicting clinical outcome and guiding therapy.
The AJCC Prognostic Stage Group containing multigene panels has been globally used from
January 1, 2018. It suggests that prognostic stage grouping should be used in countries where
biomarker tests are routinely performed, indicating that multigene molecular profiling will
become part of cancer stage evaluation and will need to be taken into consideration when
making clinical decisions [41].
Oncotype DX and MammaPrint have the strongest evidence supporting their clinical utility
and decision effectiveness in HR+ breast cancer [42]. The future of multigene panels is prom-
ising in personalizing treatment as more studies continue. However, many issues remain to be
solved before multigene panels have a wider influence on breast cancer treatment. Importantly
new issues, such as how to accurately predicate late recurrence in ER+ cancer and how to
provide more access to multigene panels, should be solved in the future.
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Newer technologies including next-generation sequencing, liquid biopsy, tumor-infiltrating
lymphocytes or PD-1 determination are at this investigational point.
3. Adjuvant chemotherapy
Several pathological factors including histological subtype, ER or PR expression, tumor grade,
lymphovascular invasion, tumor stage, and clinical factors such as patient age, preferences and
comorbidities should be taken into consideration during adjuvant chemotherapy indication is
being decided. The genomic tests and benefit–risk calculators which were developed to be
used in determining appropriate candidates for adjuvant chemotherapy in early stage HR+
breast cancer have been discussed in previous section.
Patients with HR+ breast cancer less than 5 mm and treated with only endocrine therapy have
usually very good prognosis. Thus, they typically are not treated with adjuvant chemotherapy.
However, patients with stage III HR+ breast cancer still require adjuvant chemotherapy since
they carry high risk of recurrence without chemotherapy. Many patients with HR+ HER2
negative breast cancer fall in between these two categories, and they are called as intermediate
risk group based on clinicopathological variables, genomic tests or online risk calculators.
Clinicians should inform the patients who required adjuvant chemotherapy about the risks
and benefits of chemotherapy. Risks include acute or long-term toxicities such as emesis,
alopecia, myelosuppression, neuropathy, cardiotoxicity, infertility and leukemias.
Breast cancer is the most frequent malignancy in women of reproductive age. Treatments for
breast cancer may eliminate or diminish fertility. Additionally, even in patients who do not
require chemotherapy, long duration of adjuvant endocrine therapy often leads natural decline
in ovarian reserve during adjuvant treatment.
The chemotherapy-related risk of premature ovarian insufficiency is influenced by age, body
mass index, the type and duration of therapy. After six cycles of CMF, the risk of amenorrhea is
33 and 81% in patients <40 and ≥ 40 years of age, respectively. Newer chemotherapy regimens
including adriamycin & cyclophosphamide (AC), adriamycin & cyclophosphamide & taxane
(ACT), fluorouracil & adriamycin & cyclophosphamide (FAC) and fluorouracil & adriamycin
& cyclophosphamide & taxane (FACT) result in lower rates of persisting amenorrhea. The risk
of amenorrhea is 10–20 and 13–68% in patients <30 years and in patients >30 years, respectively
[43]. Hence, the rate of infertility risk with particular chemotherapy regimen at particular age
should be discussed with patients prior to initiation of gonadotoxic therapies. Furthermore,
premenopausal women who are willing to be pregnant in the future should be referred to a
fertility specialist to be informed about various techniques of fertility preservation.
Although methods of fertility preservation in breast cancer should be a subject of a separate
chapter, fertility preservation methods can be summarized as
• established methods: oocyte or embryo cryopreservation
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• experimental methods: ovarian suppression with gonadotropin-releasing hormone (GnRH)
agonists (GnRHa) and ovarian tissue cryopreservation [44].
3.1. Chemotherapy regimen
Several polychemotherapy regimens are accepted as adjuvant chemotherapy regimen with
strong evidence in patients with early stage breast cancer. The preferred regimens vary
according to characteristics of disease, patients’ comorbidities, patients’ preferences, age, pre-
scribing doctor, institution, or country.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reports a meta-analysis periodi-
cally to review the data on adjuvant treatment of breast cancer. The previous data supported
the adjuvant chemotherapy particularly cyclophosphamide, methotrexate and fluorouracil
(CMF), anthracyclines and taxane compared with no treatment in adjuvant setting.
Trials with CMF-treated controls revealed that standard 4 AC and standard CMF were equiv-
alent (P = 067), but that anthracycline-based regimens with substantially higher cumulative
dosage than standard 4 AC [e.g., CAF or cyclophosphamide & epirubicin & fluorouracil (CEF)]
were superior to standard CMF (RR 0.78, P = 0.0004) [45]. However, NSABP B-36 randomized
phase III trial compared six cycles of FEC-100 with four cycles of standard AC in pts. with T1-
3 N0 breast cancer [46]. Primary and secondary endpoint analyses at 8 years did not reveal any
significant differences in DFS, OS, recurrence free interval (RFI), or distant RFI, although
patients and tumor characteristics were equally distributed between the two groups (<50 years
old: 40%, lumpectomy: 68%, and hormone positivity: 65%). Overall, Grade 3 and 4 expected
toxicities were more frequent in the FEC arm. Thus, international guidelines excluded six
cycles of FEC-100 from adjuvant breast cancer treatment recommendations.
In trials adding four separate cycles of a taxane to a fixed anthracycline-based control regimen,
extending treatment duration, breast cancer mortality was reduced (RR 0.86, SE 0.04, two-
sided significance P = 0.0005) [45].
In all meta-analyses involving taxane-based or anthracycline-based regimens, proportional
risk reductions were little affected by age, nodal status, tumor diameter or differentiation, ER
status, or adjuvant tamoxifen. Hence, largely independently of age (up to at least 70 years) or
the tumor characteristics currently available to us for the patients selected to be in these trials,
some taxane-plus-anthracycline-based or higher-cumulative-dosage anthracycline-based regi-
mens (not requiring stem cells) reduced breast cancer mortality about one-third.
Thus, based on these strong evidences, AC followed by a taxane (either triweekly docetaxel,
paclitaxel or two weekly or weekly paclitaxel) is now usually preferred regimen in most cases
in whom adjuvant chemotherapy is indicated.
Nonanthracycline-based chemotherapy regimens should be preferred in certain patients with
lower risk disease (node-negative), cardiac contraindication, advanced age, previous chest wall
irradiation or patients who do not accept the risks of anthracycline-based therapy. In these
patients, four cycles of docetaxel and cyclophosphamide (TC) are most preferred regimen.
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When adjuvant chemotherapy is indicated in HR+ HER2-negative early breast cancer, taxane is
mostly added to anthracycline-based regimen based on scientific data. However, patients who
cannot receive taxane due to risks of allergic reactions or peripheral neuropathy, CMF can be
administered instead of anthracycline or taxane- based regimens.
Dose-dense chemotherapy plays a controversial role in the adjuvant treatment of breast
cancer patients. Whereas meta-analyses persistently describe a significant superiority for
dose-dense treatment, the results of large phase III trials remain contradictory [47]. Some
of these trials showed important differences between the dose-dense and conventional
groups regarding number of cycles, type of drug, and total dose. Other trials are accepted
and interpreted as dose-dense but present a mixture of dose-dense and conventional
schedules.
Goldvaser et al. performed a systemic review and meta-analysis of clinical trials in which
patients with early stage breast cancer were treated with adjuvant dose-dense chemotherapy
[48]. Dose-dense treatment significantly improved DFS (HR 0.85, P < 0.001) and OS (HR 0.86,
P = 0.008). A significantly greater relative magnitude of benefit was observed in pre-
menopausal women and those with nodal involvement, but there was no influence of hormone
receptor status on results. Adjuvant dose-dense regimens improve breast cancer outcomes. It
remains uncertain whether the observed benefit reflects the impact of dose density or the
inferiority of paclitaxel every 3 weeks as a control group.
Although a direct head-to-head comparison is missing, intense dose-dense epirubicin, pacli-
taxel, and cyclophosphamide (iddETC) or four cycles each of dose-dense epirubicin/cyclophos-
phamide followed by paclitaxel are the preferred adjuvant regimens for patients at risk.
Patients with four positive lymph nodes should preferentially be treated with iddETC.
However, in EBCTCG meta-analyses, information was lacking about tumor gene expression
markers or quantitative immunohistochemistry that might help to predict risk, chemosen-
sitivity, or both.
4. Adjuvant endocrine therapy
Estrogen receptor expression is the main indicator of potential responses to endocrine therapy
(ET) which block estrogen-driven tumor growth through a variety of mechanisms. The use of
hormonal therapy in breast cancer has improved the overall outcome for patients with early-
stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple
factors, including menopausal state, patient preference, and potential side effects. Molecular
profiling has allowed therapy to be tailored for an individual patient to some extent. However,
further molecular studies are needed to individualize the choice and length of adjuvant hor-
mone therapy.
Adjuvant ET currently consists of (i) ovarian suppression, (ii) selective estrogen receptor
modulators (SERMs) and down-regulators, and (iii) AIs.
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In patients with ER+ tumors, pharmacologic ovary suppression with gonadotropin-releasing
hormone agonists in combination with standard adjuvant therapy is generally more effective
than adjuvant chemotherapy alone.
Tamoxifen is the best established SERM, has favorable effects on breast cancer control and
bone metabolism, but also has adverse effects due to its estrogenic activity in other tissues. For
these reasons, other SERMs have been developed.
Fulvestrant is an ER down-regulator with several potential advantages over SERMs, including
a 100-fold increase in its affinity for ER compared with tamoxifen and no estrogen-like activity
in the uterus.
The inhibition of the aromatase system with third-generation AIs is associated with improved
survival in patients with advanced breast cancer compared with SERMs. In postmenopausal
patients with ER+ breast cancer adjuvant treatment with AIs should be performed, either as
sequential treatment after tamoxifen or as upfront therapy.
According to NCCN guidelines [49], subdivide the adjuvant endocrine therapy recommenda-
tions in HR+ breast cancer patients based on the menopausal status of women. Three main
subgroups are (i) postmenopausal at initial diagnosis, (ii) premenopausal at initial diagnosis
and remain premenopausal after 5 years of adjuvant ET, (iii) premenopausal at initial diagno-
sis, but become postmenopausal during adjuvant ET.
i. postmenopausal at initial diagnosis:
• an AI as initial adjuvant therapy for 5 years (category 1),
• initially tamoxifen for 2–3 years followed by an AI to complete 5 years of adjuvant
ET (category 1),
• initially tamoxifen for 2–3 years followed by 5 years of AI (category 2B),
• tamoxifen for 4.5–6 years followed by 5 years of an AI (category 1) or consideration
of tamoxifen for up to 10 years.
• Five years up to 10 years of tamoxifen without AI should only be given to patients
who have a contraindication to AI.
ii. premenopausal at initial diagnosis and remain premenopausal after 5 years of adjuvant ET
• tamoxifen with or without ovarian suppression for 5 years (category 1)
• an AI with ovarian suppression for 5 years (category 1)
• tamoxifen continuing up to 10 years
iii. premenopausal at initial diagnosis, but become postmenopausal during adjuvant ET.
Decision of menopausal status is the most important point because amenorrhea does not
mean menopause, because ovaries may continue to product estrogens in amenorrheic
women. Thus, before starting AI without ovarian suppression, serum LH, FSH and estra-
diol must be evaluated.
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• After or during 5 years of tamoxifen, extend the adjuvant ETwith an AI up to 5 years
(category 1)
• After 5 years of tamoxifen, consider five additional years of tamoxifen
4.1. Combination of ovarian suppression either exemestane or tamoxifen in
premenopausal women
The initial results from the Suppression of Ovarian Function Trial (SOFT) indicate that tamox-
ifen is a suitable therapy for premenopausal women with low risk clinical-pathologic features.
For women at sufficient risk to receive chemotherapy who have premenopausal E2 levels
within 8 months of completion, the addition of ovarian suppression to tamoxifen for 5 years
resulted in some reduction of recurrence. The use of ovarian suppression combined with an AI
exemestane for 5 years resulted in further reduction of recurrence [50, 51].
The joint analysis of SOFTand Tamoxifen and Exemestane Trial (TEXT) found the combination
of ovarian suppression and exemestane significantly reduced recurrence, compared with ovar-
ian suppression plus tamoxifen. Premenopausal women with ER+ve HER2-negative breast
cancer with high-risk features can derive a meaningful improvement in 5-year invasive breast
cancer-free interval with exemestane plus ovarian suppression, as an alternative to tamoxifen.
Very young women under age 35 with ER+ve breast cancer have higher risks of recurrence,
and the use of ovarian suppression with oral endocrine therapy should be considered.
4.2. Extended adjuvant endocrine therapy beyond 5 years
Adjuvant endocrine therapy for 5 years is the standard adjuvant treatment for ER+ breast
cancer while the benefits of extended adjuvant endocrine therapy (EAET) beyond 5 years are
still controversial. In a recent meta-analysis, 5 years of adjuvant endocrine therapy only was
compared with EAET [52]. Eleven controlled trials including 29,000 women were analyzed.
There was no advantage of EAET in OS from all causes mortality (P = 0.67). On the other hand,
compared with standard therapy, the pooled effects showed that EAET was associated with
improvement in breast cancer-specific survival (OR = 0.87; P = 0.004), DFS (OR = 0.87;
P = 0.002), disease recurrence (OR = 0.76; P = 0.001), and contralateral breast recurrence
(OR = 0.74; P = 0.008). Improvement in DFS or disease recurrence was not shown in studies
that compared 5 years of tamoxifen versus tamoxifen beyond 5 years. Subgroup analysis
showed that EAET conferred more benefit for patients with positive lymph nodes. Rates of
positive lymph nodes, the study size, and the median duration of follow-up were identified as
variables that explained most of the demonstrated data heterogeneity. EAET should be consid-
ered as a preferred strategy for high-risk hormone-positive early breast cancer patients with
positive lymph nodes; however, the benefit on OS could not be demonstrated.
Extended adjuvant endocrine therapy results in increased toxicity based on the type of
extended endocrine agents. Risk of bone fractures is reported to be higher with AI, whereas
the risk of endometrial cancer and venous thromboembolism are more frequently than with
TAM. No difference was shown between AI (mono- or sequenced therapy) and TAM for
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cardiovascular events, whereas sequenced therapy compared with AI had lower risk of car-
diovascular events (moderate level of evidence).
4.3. Concurrent or sequential ovarian function suppression
Breast cancer treatment guidelines recommend that higher risk premenopausal patients
should receive ovarian function suppression as part of adjuvant endocrine therapy. However,
if chemotherapy is also given, until recently, it was uncertain whether concurrent or sequential
sequential ovarian function suppression (OFS) initiation has any detrimental effect on progno-
sis or menstruation resumption.
Recently, in a phase 3, open-label, parallel, randomized controlled trial, 216 premenopausal
patients younger than 45 years with invasive ER+ breast cancer were randomized at a 1:1 ratio
to receive (neo)adjuvant chemotherapy combined with sequential or simultaneous GnRHa
treatment between July 2009 to May 2013 [53]. All patients were advised to receive GnRHa
for at least 2 years. The rates of early menopause were 22.8% (21/92) in the sequential group
and 23.1% (18/78) in the simultaneous group (simultaneous vs. sequential: OR 1.01; P = 0.969;
age-adjusted OR 1.13; P = 0.737). The median menstruation resumption period was
12.0 months and 10.3 months for the sequential and simultaneous groups, respectively (HR
0.83; P = 0.274; age-adjusted HR 0.90; P = 0.567). During a median follow-up time of
56.9 months (IQR 49.5–72.4 months), there were no significant differences in disease-free
survival (P = 0.290) or in overall survival (P = 0.514) between the two groups.
In an exploratory analysis of phase III TEXT and SOFT trials, 1872 patients who received
adjuvant chemotherapy for HR+, HER2-negative breast cancer and upon randomization to an
OFS-containing adjuvant endocrine therapy, initiated GnRHa triptorelin were analyzed [54].
Breast cancer-free interval (BCFI) was compared between patients who received OFS concur-
rently with chemotherapy in TEXT (n = 1242) versus sequentially post-chemotherapy in SOFT
(n = 630). Because timing of trial enrollment relative to adjuvant chemotherapy differed,
landmark analysis was implemented to re-define BCFI beginning 1 year after final dose of
chemotherapy (median, 15.5 months in TEXT and 8.1months from enrollment to landmark in
SOFT). The median duration of adjuvant chemotherapy was 18weeks in both groups. Patients
who were premenopausal post-chemotherapy in SOFT were younger on average. After post-
landmark median follow-up of about 5 years, post-landmark BCFI was found to be statistically
similar between concurrent use of triptorelin with chemotherapy and sequential use of
triptorelin after chemotherapy, either in the overall population (HR = 1.11; P = 0.72; 4-year
BCFI 89% in both groups), or in the subgroup of 692 women < 40 years at diagnosis (HR = 1.13)
who are less likely to develop chemotherapy-induced amenorrhea.
Because the sequential use of GnRHa and chemotherapy showed similar ovarian preservation
and survival outcomes when compared with simultaneous use ER+ premenopausal patients,
addition of GnRHa to oncologic treatment can probably be delayed until menstruation resump-
tion after chemotherapy. However, based on comparative-effectiveness modeling of TEXT and
SOFTafter about 5years median follow-up, concurrent administration of OFS with chemotherapy
is neither detrimental nor beneficial effect on the efficacy of adjuvant therapy which includes
chemotherapy, with limited statistical power especially for the subgroup < 40years.
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5. Adjuvant bisphosphonates
Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop
evidence-based recommendations by a systematic review of the literature [55]. The women
with natural menopause or the women who were postmenopausal induced by ovarian sup-
pression or ablation were included. Adjuvant bisphosphonates were reported to reduce bone
recurrence and improve survival in postmenopausal women with early stage breast cancer.
Absolute benefit was found to be greater in patients who are at higher risk of recurrence, and
almost all trials were conducted in patients who also received systemic therapy. The data are
extremely limited for bisphosphonates other than zoledronic acid or clodronate due to most
studies performed with these two bisphosphonates. ASCO clinical guidelines recommends
that, if available, zoledronic acid (4 mg intravenously every 6 months) or clodronate
(1600 mg/d orally) be considered as an adjuvant therapy for postmenopausal patients with
breast cancer who are deemed candidates for adjuvant systemic therapy. However, further
research comparing different bone-modifying agents, doses, dosing intervals, and durations is
required. Risk factors for osteonecrosis of the jaw and renal impairment should be assessed,
and any pending dental or oral health problems should be dealt with prior to starting treat-
ment. While adjuvant denosumab reduces fractures and it looks promising in adjuvant setting,
long-term survival data are still insufficient to make any recommendation. The use of these
agents to reduce fragility fractures in patients with low bone mineral density is beyond the
scope of the guideline.
6. Promising targeted agents
Ongoing studies are evaluating the role of additional targeted therapies, such as CDK4/6
inhibitors including ribociclib, palbociclib, to further improve outcome for patients with
early-stage HR+ breast cancer.
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